Impact of brain natriuretic peptide reduction on the worsening renal function in patients with acute heart failure.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 10 02 2020
accepted: 16 06 2020
entrez: 27 6 2020
pubmed: 27 6 2020
medline: 5 9 2020
Statut: epublish

Résumé

The prognostic impact of worsening renal function (WRF) in patients with acute heart failure (AHF) remains under debate. Successful decongestion might offset the negative impact of WRF, but little is known about indicators of successful decongestion in the very acute phase of AHF. We hypothesized that decongestion as evaluated by the percent reduction in brain natriuretic peptide (BNP) could identify relevant prognostic implications of WRF in the very acute phase of AHF. Data on 907 consecutive hospitalized patients with AHF in the REALITY-AHF study (age: 78±12 years; 55.1% male) were analyzed. Creatinine and BNP were measured at baseline and 48 hours from admission. WRF was defined as an increase in creatinine >0.3 mg at 48 hours from admission. The primary endpoint was 1-year all-cause mortality. Patients were divided into four groups according to the presence/absence of WRF and a BNP reduction higher/lower than the median: no-WRF/higher-BNP-reduction (n = 390), no-WRF/lower-BNP-reduction (n = 397), WRF/higher-BNP-reduction (n = 63), and WRF/lower-BNP-reduction groups (n = 57). Kaplan-Meier curve analysis showed that the WRF/lower-BNP-reduction group had a worse prognosis than the other groups. In a Cox regression analysis, only the WRF/lower-BNP-reduction group had higher mortality compared to the no-WRF/higher-BNP-reduction group (hazard ratio: 3.34, p<0.001). In the very acute phase of AHF, BNP reduction may aid in identifying relevant prognostic significance of WRF.

Identifiants

pubmed: 32589688
doi: 10.1371/journal.pone.0235493
pii: PONE-D-20-03923
pmc: PMC7319326
doi:

Substances chimiques

Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0235493

Déclaration de conflit d'intérêts

Dr. Yuya Matsue is affiliated with a department endowed by Philips Respironics, ResMed, Teijin Home Healthcare, and Fukuda Denshi; received an honorarium from Otsuka Pharmaceutical Co.; and received consulting fees from Edwards Lifesciences and Bristol-Myers Squibb. Other authors have nothing to declare. These conflicts of interests do not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

J Am Coll Cardiol. 2008 Aug 12;52(7):534-40
pubmed: 18687247
Clin Chim Acta. 2013 Sep 23;424:287-91
pubmed: 23850775
Eur Heart J. 2014 Feb;35(7):455-69
pubmed: 24164864
Heart Lung Circ. 2017 Mar;26(3):226-234
pubmed: 27523462
Clin Chim Acta. 2012 Dec 24;414:112-9
pubmed: 22910582
Circ J. 2018 Dec 25;83(1):174-181
pubmed: 30429431
J Card Fail. 2019 Sep;25(9):712-721
pubmed: 30965102
Am J Cardiovasc Drugs. 2019 Dec;19(6):597-605
pubmed: 31218508
Eur Heart J. 2004 Feb;25(4):292-9
pubmed: 14984917
Circ Heart Fail. 2018 May;11(5):e004644
pubmed: 29748350
Clin Chim Acta. 2015 Mar 30;443:17-24
pubmed: 24937843
Eur J Heart Fail. 2017 Feb;19(2):226-236
pubmed: 27758007
J Am Coll Cardiol. 2002 May 15;39(10):1623-9
pubmed: 12020489
J Card Fail. 2001 Mar;7(1):21-9
pubmed: 11264546
Am J Cardiol. 2018 Apr 15;121(8):969-974
pubmed: 29477488
Circulation. 2010 Jul 20;122(3):265-72
pubmed: 20606118
Am J Cardiol. 2011 Jan;107(1):74-8
pubmed: 21146690
J Card Fail. 2016 Oct;22(10):753-60
pubmed: 27374839
Eur Heart J. 2010 Apr;31(7):832-41
pubmed: 19906690
Circ Heart Fail. 2012 Jan;5(1):54-62
pubmed: 22167320
Circulation. 1993 Jul;88(1):107-15
pubmed: 8319323
Stat Med. 1999 Mar 30;18(6):681-94
pubmed: 10204197
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Heart Fail. 2011 Sep;13(9):961-7
pubmed: 21622980
J Card Fail. 2019 Jan;25(1):12-19
pubmed: 30219549
Open Heart. 2018 Jul 11;5(2):e000845
pubmed: 30018782
Eur Heart J. 2014 May 14;35(19):1284-93
pubmed: 24585267
Circulation. 2018 Apr 17;137(16):1671-1683
pubmed: 29242350
BMJ. 2005 Mar 19;330(7492):625
pubmed: 15774989
Circ Heart Fail. 2013 Mar;6(2):240-5
pubmed: 23250981
J Am Coll Cardiol. 2017 Jun 27;69(25):3042-3051
pubmed: 28641794
Congest Heart Fail. 2009 Nov-Dec;15(6):256-64
pubmed: 19925503

Auteurs

Kenji Yoshioka (K)

Department of Cardiology, Kameda Medical Center, Chiba, Japan.
Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Yuya Matsue (Y)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Takahiro Okumura (T)

Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Keisuke Kida (K)

Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan.

Shogo Oishi (S)

Department of Cardiology, Himeji Cardiovascular Center, Hyogo, Japan.

Eiichi Akiyama (E)

Division of Cardiology, Yokohama City University Medical Center, Kanagawa, Japan.

Satoshi Suzuki (S)

Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.

Masayoshi Yamamoto (M)

Cardiovascular Division, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.

Akira Mizukami (A)

Department of Cardiology, Kameda Medical Center, Chiba, Japan.

Shunsuke Kuroda (S)

Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, United States of America.

Nobuyuki Kagiyama (N)

Department of Cardiology, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Tetsuo Yamaguchi (T)

Department of Cardiology, Cardiovascular Center, Toranomon Hospital, Tokyo, Japan.

Tetsuo Sasano (T)

Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Akihiko Matsumura (A)

Department of Cardiology, Kameda Medical Center, Chiba, Japan.

Takeshi Kitai (T)

Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH